Neuroblastoma is a pediatric solid tumor characterized by dysregulation of the CDK-RB-E2F axis, leading to elevated E2F activity, uncontrolled progression through the G1/S transition and an aggressive tumor phenotype. Researchers from Circle Pharma Inc. and collaborators presented preclinical data on CID-078, a first-in-class oral macrocycle with dual cyclin A and B RxL inhibitory activity, in models of neuroblastoma.
Teva Pharmaceutical Industries Ltd. has commenced IND-enabling studies with BD-9, a dual-specific multibody targeting thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13). By simultaneously blocking two key drivers of TH2-driven inflammation, BD-9 has the potential to improve outcomes for patients with conditions such as atopic dermatitis and asthma.
Phosphoinositide signaling pathways have been implicated in the metabolic alterations associated with various human diseases, including breast cancer. The phosphatidylinositol-5-phosphate 4-kinase (PIP4K) family catalyzes the phosphorylation of phosphatidylinositol-5-phosphate (PI5P) to produce phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), a lipid that regulates signaling pathways associated with cancer cell growth and metastasis.
The variety of blood cells decreases with age. Some are lost, while others become dominant, leading to a loss of functional diversity. This, in turn, weakens the immune system in older individuals and increases the risk of developing hematological diseases. Scientists in Barcelona have developed a method based on DNA methylation that works like a barcode. EPI-Clone identifies and traces the origin of blood cells to measure the complexity of these clones in aging humans and mice.
More and more, artificial intelligence is becoming inseparable from drug development. But it needs to be well integrated with the right people and support technologies in order to be successful, according to Josep Bassaganya-Riera, the founder and CEO of Nimmune Biopharma Inc. With more than 20 years in the industry, he shared his insights and experience about the crucial importance of getting technology and people in balance.
Otsuka Pharmaceutical Co. Ltd. has described macrophage colony-stimulating factor 1 receptor (CSF1R; CD115; c-Fms) inhibitors reported to be useful for diagnosis and treatment of pain, infections, amyotrophic lateral sclerosis, multiple sclerosis, cardiovascular disorders, Alzheimer’s disease and Parkinson’s disease, among others.
Eli Lilly & Co. has divulged aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of psoriasis, atopic dermatitis, ulcerative colitis, Crohn’s disease, graft-versus-host disease, rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis.
Bpgbio Inc. has synthesized bifunctional compounds comprising an E2 ubiquitin ligase binding ligand covalently linked to an estrogen receptor α (ER-α; ESR1) targeting moiety through a linker acting as ESR1 degradation inducers reported to be useful for the treatment of cancer.
Dong-A ST Co. Ltd. has disclosed transcriptional enhancer factor (TEAD) and/or transcriptional coactivator YAP1/TEAD interaction inhibitors reported to be useful for the treatment of cancer.
RSS
